LOVENOX treatment lowered the risk of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE).1
Outcomes of medical patients with restricted mobility treated with 7 days (median duration) of 40 mg LOVENOX daily subcutaneously:
At approximately 3 months following enrollment, the incidence of venous thromboembolism remained lower in the LOVENOX 40 mg treatment group versus the placebo treatment group.
Safety endpoints (LOVENOX vs placebo)1
Major bleeding: 3(<1%) vs 2(<1%)
Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of >= 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial. The rates represent major bleeding on study medication up to 24 hours after last dose.
In a study of medical patients with severely restricted mobility during acute illness, LOVENOX was dosed for no more than 14 days, and most patients were treated for 6 to 11 days in this study (median 7 days).
ARR=absolute risk reduction
aP value calculated based on chi-square test.1
In a double blind study, medical patients with severely restricted mobility during acute illness were treated with LOVENOX 20 mg or 40 mg once a day subcutaneously. The study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or chronic respiratory insufficiency; acute infection; or acute rheumatic disorder. A total of 1,073 patients, ages ranging from 40 to 97 years, were treated.
In Acutely Ill Medical Patients
LOVENOX has proven outcomes in once-daily dosing of medically ill patients, offering:
|Medical patients during acute illness|
|Dosing||40 mg subcutaneously once daily|
Many hospitalized, acutely ill medical patients and surgical patients may develop DVT/PE as outpatients.
Appropriate length of DVT prophylaxis begins in the hospital and may continue with outpatient therapy.
|Acute medical illness|
|Average hospital LOS||5 days|
|Usual duration of
administration with LOVENOX
Warning: spinal/epidural hematoma
Epidural or spinal hematomas may occur in
patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids
and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis.